𝛼SK or Searchbullish
BillionToOne At $153M/yr
94 Views06 Feb 2025 08:00
TL;DR: Offering genetic testing to expecting mothers with a non-invasive blood draw rather than invasive amniocentesis, Sacra estimates BillionToOne crossed $100M in revenue in 2024, generating $153M (up 113% YoY). Now, as they expand to cancer therapy selection and monitoring, they’re competing with Natera, Myriad Genetics, and Guardant Health. For more, check out our full report and dataset on BillionToOne...
What is covered in the Full Insight:
- Introduction
- Growth and Financial Performance
- Technology and Product Offerings
- Market Expansion and Competition
- Conclusion and Future Outlook
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- BillionToOne At $153M/yr06 Feb 2025
x